3 July 2024
Freshfields advises Shanghai Henlius Biotech, Inc. on its proposed privatisation
Advising firms
Deal team
5 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Edward Freeman Lead | Freshfields | Partner | Not stated | Not stated |
| Grace Huang Lead | Freshfields | Partner | Not stated | Not stated |
| David Yi Lead | Freshfields | Partner | Not stated | Not stated |
| Kelly Huang | Freshfields | Senior associate | Not stated | Not stated |
| Haohan Li | Freshfields | Associate | Not stated | Not stated |
2 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- Not stated
- What the figure measures
- Not stated
- Client
- Shanghai Henlius Biotech, Inc.Target
- Counterparties
- Shanghai Fosun New Medicine Research Company Limited (Buy-side)